Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $314.00

by · The Cerbat Gem

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target boosted by Bank of America from $307.00 to $314.00 in a research report sent to investors on Monday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

ALNY has been the topic of a number of other research reports. TD Cowen upped their price target on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Stifel Nicolaus upped their price target on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Evercore ISI upped their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, June 25th. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Finally, Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Six analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $286.82.

Get Our Latest Analysis on ALNY

Alnylam Pharmaceuticals Trading Down 1.3 %

NASDAQ ALNY opened at $296.75 on Monday. The business’s 50 day moving average is $271.29 and its two-hundred day moving average is $215.60. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market capitalization of $37.54 billion, a price-to-earnings ratio of -110.73 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. The business’s revenue was up 107.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.21) EPS. Equities analysts forecast that Alnylam Pharmaceuticals will post -2.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,829,070. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock valued at $13,595,460 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC increased its holdings in Alnylam Pharmaceuticals by 24.7% in the 3rd quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock valued at $609,000 after purchasing an additional 439 shares in the last quarter. Swedbank AB lifted its stake in shares of Alnylam Pharmaceuticals by 160.3% in the third quarter. Swedbank AB now owns 53,729 shares of the biopharmaceutical company’s stock worth $14,777,000 after acquiring an additional 33,090 shares in the last quarter. Creative Planning lifted its stake in shares of Alnylam Pharmaceuticals by 24.6% in the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock worth $2,754,000 after acquiring an additional 1,978 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Alnylam Pharmaceuticals by 4.0% in the third quarter. Exchange Traded Concepts LLC now owns 3,568 shares of the biopharmaceutical company’s stock worth $981,000 after acquiring an additional 136 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt lifted its stake in shares of Alnylam Pharmaceuticals by 400.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,000 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 800 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

See Also